Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jeffrey Gudin, Andrew G Kaufman & Samyadev Datta. (2020) Are Opioids Needed to Treat Chronic Low Back Pain? A Review of Treatment Options and Analgesics in Development. Journal of Pain Research 13, pages 1007-1022.
Read now
Read now
Mellar P. Davis. (2016) Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain. Expert Opinion on Drug Metabolism & Toxicology 12:7, pages 823-831.
Read now
Read now
Articles from other publishers (41)
Salomon Poliwoda, Bryant Noss, Gia Thinh D. Truong, Zachary A. Creech, Sarang S. Koushik, Ivan Urits & Omar Viswanath. (2023) The Utilization of Low Dose Naltrexone for Chronic Pain. CNS Drugs 37:8, pages 663-670.
Crossref
Crossref
Lon V. Kendall, Vanessa L. Oliver & Trinka W. Adamson. 2023. Anesthesia and Analgesia in Laboratory Animals. Anesthesia and Analgesia in Laboratory Animals
139
185
.
Martiniano Bello. (2022) Molecular Basis of Inhibitory Mechanism of Naltrexone and Its Metabolites through Structural and Energetic Analyses. Molecules 27:15, pages 4919.
Crossref
Crossref
Marta Peciña, Jiazhou Chen, Thandi Lyew, Jordan F. Karp & Alexandre Y. Dombrovski. (2021) μ Opioid Antagonist Naltrexone Partially Abolishes the Antidepressant Placebo Effect and Reduces Orbitofrontal Cortex Encoding of Reinforcement. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 6:10, pages 1002-1012.
Crossref
Crossref
Elizabeth Hatfield, Kristine Phillips, Sahar Swidan & Lawrence Ashman. (2020) Use of low-dose naltrexone in the management of chronic pain conditions. The Journal of the American Dental Association 151:12, pages 891-902.e1.
Crossref
Crossref
J. Chen, A. Mizuno, T. Lyew, H. T. Karim, J. F. Karp, A. Y. Dombrovski & M. Peciña. (2020) Naltrexone modulates contextual processing in depression. Neuropsychopharmacology 45:12, pages 2070-2078.
Crossref
Crossref
Diana Trofimovitch & Steven J. Baumrucker. (2019) Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes. American Journal of Hospice and Palliative Medicine® 36:10, pages 907-912.
Crossref
Crossref
Laurel S. Morris, Kwangyeol Baek, Roger Tait, Rebecca Elliott, Karen D. Ersche, Remy Flechais, John McGonigle, Anna Murphy, Liam J. Nestor, Csaba Orban, Filippo Passetti, Louise M. Paterson, Ilan Rabiner, Laurence Reed, Dana Smith, John Suckling, Eleanor M. Taylor, Edward T. Bullmore, Anne R. Lingford-Hughes, Bill Deakin, David J. Nutt, Barbara J. Sahakian, Trevor W. Robbins & Valerie Voon. (2018) Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. Addiction Biology 23:1, pages 425-436.
Crossref
Crossref
Cheyenne Allenby & Mary Falcone. (2017) Using Genetics to Improve Addiction Treatment Outcomes. Current Behavioral Neuroscience Reports 4:1, pages 1-9.
Crossref
Crossref
Yan Sun, Yan Zhang, Fan Wang, Yankun Sun, Jie Shi & Lin Lu. (2016) From genetic studies to precision medicine in alcohol dependence. Behavioural Pharmacology 27:2 and 3 - Special Issue, pages 87-99.
Crossref
Crossref
Jarred Younger, Luke Parkitny & David McLain. (2014) The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology 33:4, pages 451-459.
Crossref
Crossref
David J Nutt. (2013) The role of the opioid system in alcohol dependence. Journal of Psychopharmacology 28:1, pages 8-22.
Crossref
Crossref
Vibhuti Srivastava & David Goldman. 2011. Neuroimaging in Addiction. Neuroimaging in Addiction
285
317
.
Jessica E. Sturgess, Tony P. George, James L. Kennedy, Andreas Heinz & Daniel J. Müller. (2011) Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addiction Biology 16:3, pages 357-376.
Crossref
Crossref
Jinmin Zhu, Thomas J. Spencer, Lee-Yuan Liu-Chen, Joseph Biederman & Pradeep G. Bhide. (2011) Methylphenidate and μ opioid receptor interactions: A pharmacological target for prevention of stimulant abuse. Neuropharmacology 61:1-2, pages 283-292.
Crossref
Crossref
H C Jackson & R D E Sewell. (1984) The role of opioid receptor sub-types in tifluadom-induced feeding. Journal of Pharmacy and Pharmacology 36:10, pages 683-686.
Crossref
Crossref
Kimberly L. KjomeF. Gerard Moeller. (2011) Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence. Substance Abuse: Research and Treatment 5, pages SART.S5452.
Crossref
Crossref
W. O. Farid, D. McCallum, R. J. Tait, S. A. Dunlop & G. K. Hulse. (2009) Minor pathological changes are induced by naltrexone-poly(DL-lactide) implants in pregnant rats. Journal of Biomedical Materials Research Part A 91A:4, pages 964-974.
Crossref
Crossref
Sung Il Jung, Cheong Hoon Seo, Kiun Jang, Byung Joo Ham, Ihn-Geun Choi, Jong-Hyun Kim & Boung Chul Lee. (2009) Efficacy of Naltrexone in the Treatment of Chronic Refractory Itching in Burn Patients: Preliminary Report of an Open Trial. Journal of Burn Care & Research 30:2, pages 257-260.
Crossref
Crossref
Fazlul Huq .. (2006) Molecular Modelling Analysis of the Metabolism of Naltrexone. Journal of Pharmacology and Toxicology 1:4, pages 354-361.
Crossref
Crossref
Gantt P Galloway, Monika Koch, Ryan Cello & David E Smith. (2005) Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry 5:1.
Crossref
Crossref
Adrian Mutlow, Ramiro Isaza, James W. Carpenter, David E. Koch & Robert P. Hunter. (2004) PHARMACOKINETICS OF CARFENTANIL AND NALTREXONE IN DOMESTIC GOATS (CAPRA HIRCUS). Journal of Zoo and Wildlife Medicine 35:4, pages 489-496.
Crossref
Crossref
Stefan W Toennes, Gerold F Kauert, Sabine M Grüsser, Werner Jäkel & Gerlinde Partecke. (2004) Determination of naltrexone and 6-β-naltrexol in human plasma following implantation of naltrexone pellets using gas chromatography–mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 35:1, pages 169-176.
Crossref
Crossref
Grace O’Leary, Jennifer Borrow & Roger D. Weiss. (2001) Opioid antagonists in the treatment of alcohol dependence. Current Psychiatry Reports 3:6, pages 484-488.
Crossref
Crossref
Chooi Fen Chan, Gregory M. Chiswell, Roberta Bencini, L.Peter Hackett, Leon J. Dusci & Kenneth F. Ilett. (2001) Quantification of naltrexone and 6,β-naltrexol in plasma and milk using gas chromatography–mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 761:1, pages 85-92.
Crossref
Crossref
Annie-Kim Gilbert & Keith B.J Franklin. (2001) Characterization of the analgesic properties of nomifensine in rats. Pharmacology Biochemistry and Behavior 68:4, pages 783-787.
Crossref
Crossref
Laura Cousino Klein, Larry D. Jamner, Janel Alberts, Matthew D. Orenstein, Linda Levine & Hoyle Leigh. (2007) Sex Differences in Salivary Cortisol Levels Following Naltrexone Administration1. Journal of Applied Biobehavioral Research 5:2, pages 144-153.
Crossref
Crossref
Anna Ferrari, Marco Bertolotti, Alessandra Dell'Utri, Ustik Avico & Emilio Sternieri. (1998) Serum time course of naltrexone and 6β-naltrexol levels during long term treatment in drug addicts. Drug and Alcohol Dependence 52:3, pages 211-220.
Crossref
Crossref
R. Szczepanska, S. Harding & L.A. Grupp. (1996) Characterization of the decline in alcohol consumption by aminopeptidase inhibition. Drug and Alcohol Dependence 43:3, pages 133-141.
Crossref
Crossref
Thomas J. Martin, Lois E. Walker, Glen M. Sizemore, James E. Smith & Steven I. Dworkin. (1996) Within-session determination of dose-response curves for heroin self-administration in rats: comparison with between-session determination and effects of naltrexone. Drug and Alcohol Dependence 41:2, pages 93-100.
Crossref
Crossref
M. J. Kreek. 1996. Pharmacological Aspects of Drug Dependence. Pharmacological Aspects of Drug Dependence
563
598
.
Hemendra N. Bhargava, A. Karl Larsen, Nafasat H. Rahmani & Vincent M. Villar. (1993) Naltrexone-induced alterations of the distribution of morphine in brain regions and spinal cord of the rat. Brain Research 607:1-2, pages 1-8.
Crossref
Crossref
Helen C. Jackson, I.J. Griffin & D.J. Nutt. (1992) Endogenous opioids may be involved in idazoxan-induced food intake. Neuropharmacology 31:8, pages 771-776.
Crossref
Crossref
Hussein Abou-Issa & Gopi A. Tejwani. (1991) Antitumor activity of naltrexone and correlation with steroid hormone receptors. Biochemical and Biophysical Research Communications 175:2, pages 625-630.
Crossref
Crossref
Tracy K. McIntosh, Marc Palter, Robert Grasberger, Richard Vezina, Lee Gerstein, Neil Yeston & Richard H. Egdahl. (1986) Endorphins in primate hemorrhagic shock: Beneficial action of opiate antagonists. Journal of Surgical Research 40:3, pages 265-275.
Crossref
Crossref
Karl Verebey. 1984. Social and Medical Aspects of Drug Abuse. Social and Medical Aspects of Drug Abuse
169
183
.
Mark S. Gold, Charles A. Dackis, A. L. C. Pottash, Harvey H. Sternbach, William J. Annitto, David Martin & Marcy Pasternak Dackis. (2006) Naltrexone, opiate addiction, and endorphins. Medicinal Research Reviews 2:3, pages 211-246.
Crossref
Crossref
Thomas M. Lehman, Padma Pyati & George R. Peterson. (1979) Inhibition of drug metabolism by chronically administered naltrexone. Life Sciences 25:18, pages 1591-1600.
Crossref
Crossref
Shimon Amir, Richard Blair & Zalman Amit. (1979) Increased amphetamine potency following chronic naltrexone administration in rats. Life Sciences 25:16, pages 1407-1412.
Crossref
Crossref
M.O. MAYKUT. 1978. Neuro-Psychopharmacology. Neuro-Psychopharmacology
245
258
.
M.O. Maykut. (1977) Pharmacotherapy of narcotic dependence. Progress in Neuro-Psychopharmacology 1:1-2, pages 31-49.
Crossref
Crossref